A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

NCT03758612 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis
Tuberculosis, Pulmonary

Interventions

DRUG: TBI-223 oral suspension
DRUG: TBI-223 enteric capsule
DRUG: TBI-223 SR Tablet Prototype 1
DRUG: TBI-223 SR Tablet Prototype 2
DRUG: TBI-223 SR Tablet Prototype 3
DRUG: TBI-223 IR Tablet
DRUG: Placebo suspension

Sponsor

Global Alliance for TB Drug Development